Update

2018 AASLD guidance recommends OCALIVA as the only approved second-line treatment option for PBC3 SEE THE GUIDELINES

OCALIVA Drug-to-Drug Interactions1

Interaction Recommendation
Bile acid binding resins (eg, cholestyramine, colestipol, or colesevelam) adsorb and reduce bile acid absorption and may reduce the absorption, systemic exposure, and efficacy of OCALIVA If taking bile acid binding resins, instruct patients to take OCALIVA at least 4 hours before or 4 hours after (or at as great an interval as possible) taking a bile acid binding resin
International normalized ratio (INR) is decreased following coadministration of warfarin and OCALIVA Monitor INR and adjust the dosage of warfarin, as needed, to maintain target INR range when coadministering OCALIVA and warfarin
OCALIVA may increase exposure to concomitant drugs that are CYP1A2 substrates with a narrow therapeutic index (eg, theophylline and tizanidine) Therapeutic monitoring of CYP1A2 substrates with a narrow therapeutic index (eg, theophylline and tizanidine) is recommended when coadministered with OCALIVA
Inhibitors of bile salt efflux pump (BSEP) may exacerbate accumulation of conjugated bile salts including taurine conjugate of OCALIVA in the liver and result in clinical symptoms Avoid concomitant use of inhibitors of BSEP, such as cyclosporine. If concomitant use is deemed necessary, monitor serum transaminases and bilirubin
OCALIVA obeticholic acid OCALIVA obeticholic acid

Enroll for updates

Get the emails you want about OCALIVA:

  • You choose the topics
  • Content is intended for US healthcare professionals

REGISTER FOR UPDATES

Register for Updates Close

*Required fields. Invalid entry. Please try again.

First name required
Last name required
Email required
Specialty Profession required


REGISTER


 

Thank you for your interest

You can expect a confirmation email shortly to set your preferences.

Reference:

  1. OCALIVA [package insert]. New York, NY: Intercept Pharmaceuticals, Inc.; 2018.
OCALICA obeticholic acid

Enroll for updates

REGISTER FOR UPDATES

Register for Updates Close

*Required fields. Invalid entry. Please try again.

First name required
Last name required
Email required
Specialty Profession required


REGISTER


 

Thank you for your interest

You can expect a confirmation email shortly to set your preferences.

OCALIVA® (obeticholic acid)

Patient Assistance: 1-844-622-4278

This site is intended for US healthcare professionals only Home Visit Patient Site Prescribing Information Important Safety Information

Patient Assistance:
1-844-622-4278

You are about to leave Ocalivahcp.com

Click CONTINUE to go to the page you requested or click CANCEL to remain on this page.

Cancel Continue